UPDATE - UBS Initiates Coverage on Verstem (VSTM) with a Buy; New Approach To An Old Problem

March 7, 2012 1:15 PM EST Send to a Friend
Get Alerts VSTM Hot Sheet
Price: $9.30 +1.31%

Rating Summary:
    11 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 3 | Down: 17 | New: 2
Trade VSTM Now!
Join SI Premium – FREE
UPDATE - UBS initiates coverage on Verstem (Nasdaq: VSTM) with a Buy rating. PT $20.

UBS analyst says, "VSTM is an early-stage biotechnology company that we view as uniquely positioned to leverage recent advances in cancer genetics and develop products that could overcome multidrug resistance to chemotherapy. We think at least one of its 3 late preclinical assets has the potential to reach proof of concept in “triple-negative” breast cancer, which would trigger significant valuation step-ups over 1-3 years."


To see more ratings on VSTM, Click Here


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

New Coverage

Related Entities

UBS

Add Your Comment